Clinical Trials Browser

Phase 1 × INDUSTRY × brigatinib × Clear all

NCT03420742 2023-01-27

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

Phase 1 Completed

24 enrolled 17 charts

Carcinoma, Lung Neoplasms, Neoplasms